# Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer

> **NCT01075113** · PHASE1 · COMPLETED · sponsor: **Virginia Commonwealth University** · enrollment: 16 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** sorafenib tosylate
- **DRUG:** vorinostat

## Key facts

- **NCT ID:** NCT01075113
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-10
- **Primary completion:** 2017-02-02
- **Final completion:** 2019-07-18
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01075113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01075113, "Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01075113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*